Document Detail


Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
MedLine Citation:
PMID:  19808428     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Onset of atrial fibrillation (AF) has been linked to changes in autonomic tone, with increasing heart rate (HR) immediately before AF onset in some patients suggesting a possible role of acute increases in sympathetic activity in AF onset. Although losartan therapy and decreasing ECG left ventricular hypertrophy are associated with decreased AF incidence, the relationship of HR changes over time to development of AF has not been examined. METHODS AND RESULTS: HR was evaluated in 8828 hypertensive patients without AF by history or on baseline ECG in the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. Patients were treated with losartan- or atenolol-based regimens and followed with serial ECGs annually which were used to determine HR and ECG left ventricular hypertrophy by Cornell product and Sokolow-Lyon voltage criteria. During mean follow-up of 4.7+/-1.1 years, new-onset AF occurred in 701 patients (7.9%). Patients with new AF had smaller decreases in HR to last in-treatment ECG or last ECG before AF (-2.7+/-13.5 versus -5.2+/-12.5 bpm), whether on losartan- (-0.4+/-13.5 versus -2.2+/-11.7 bpm) or atenolol-based treatment (-5.3+/-12.8 versus -8.3+/-12.6 bpm, all P<0.001). In univariate Cox analyses, higher HR on in-treatment ECGs was associated with an increased risk of new-onset AF, with a 15% greater risk of AF for every 10 bpm higher HR (95% CI 8% to 22%). In alternative analyses, persistence or development of a HR> or =84 (upper quintile of baseline HR) was associated with a 46% greater risk of developing AF (95% CI 19% to 80%). After adjusting for treatment with losartan versus atenolol, baseline risk factors for AF, baseline and in-treatment systolic and diastolic pressure and the known predictive value of baseline and in-treatment ECG left ventricular hypertrophy for new AF, higher in-treatment HR remained strongly associated with new AF with a 19% higher risk for every 10 bpm higher HR (95% CI 10% to 28%) or a 61% increased rate of AF in patients with persistence or development of a HR> or =84 (95% CI 27% to 104%, all P<0.001). CONCLUSIONS: Higher in-treatment HR on serial ECGs is associated with an increased likelihood of new-onset AF, independent of treatment modality, blood pressure lowering, and regression of ECG left ventricular hypertrophy in patients with essential hypertension.
Authors:
Peter M Okin; Kristian Wachtell; Sverre E Kjeldsen; Stevo Julius; Lars H Lindholm; Björn Dahlöf; Darcy A Hille; Markku S Nieminen; Jonathan M Edelman; Richard B Devereux
Related Documents :
10654548 - Atrial fibrillation after cardiac operation: risks, mechanisms, and treatment.
15894598 - High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and pro...
12670638 - Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial ...
20206318 - Verapamil eliminates the hierarchical nature of activation frequencies from the pulmona...
8357338 - Ace-inhibitors and coronary microcirculation.
12751128 - Isolated bundle branch block and left ventricular dysfunction.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2008-12-02
Journal Detail:
Title:  Circulation. Arrhythmia and electrophysiology     Volume:  1     ISSN:  1941-3084     ISO Abbreviation:  Circ Arrhythm Electrophysiol     Publication Date:  2008 Dec 
Date Detail:
Created Date:  2009-10-07     Completed Date:  2009-10-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101474365     Medline TA:  Circ Arrhythm Electrophysiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  337-43     Citation Subset:  IM    
Affiliation:
Greenberg Division of Cardiology, Weill Cornell Medical College, New York, NY 10065, USA. pokin@med.cornell.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use*
Aged
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Antihypertensive Agents / therapeutic use*
Atenolol / therapeutic use*
Atrial Fibrillation / etiology,  physiopathology,  prevention & control*
Blood Pressure / drug effects
Double-Blind Method
Electrocardiography
Female
Heart Rate / drug effects*
Humans
Hypertension / complications,  drug therapy*,  physiopathology
Hypertrophy, Left Ventricular / etiology,  physiopathology,  prevention & control*
Incidence
Kaplan-Meiers Estimate
Losartan / therapeutic use*
Male
Middle Aged
Proportional Hazards Models
Prospective Studies
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 114798-26-4/Losartan; 29122-68-7/Atenolol
Comments/Corrections
Comment In:
Circ Arrhythm Electrophysiol. 2008 Dec;1(5):321-3   [PMID:  19808425 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  ECG quantification of myocardial scar in cardiomyopathy patients with or without conduction defects:...
Next Document:  Chronic atrial fibrillation is a biatrial arrhythmia: data from catheter ablation of chronic atrial ...